Literature DB >> 28231744

The Use of Chinese Herbal Medicine in the Treatment of Chronic Obstructive Pulmonary Disease (COPD).

Yen-Nung Liao1, Wen-Long Hu1,2,3, Hsuan-Ju Chen4,5, Yu-Chiang Hung1,6.   

Abstract

In Oriental countries, combinations of Chinese herbal products (CHPs) are often utilized as therapeutic agents for chronic obstructive pulmonary disease (COPD). The effects of CHPs on COPD have been previously reported. This study aimed to analyze the frequency of prescription and usage of CHPs in patients with COPD in Taiwan. In this nationwide population-based cross-sectional study, 19,142 patients from a random sample of one million individuals in the Longitudinal Health Insurance Database 2000 (LHID 2000) of the National Health Insurance Research Database (NHIRD) were enrolled from 2000 to 2011. The multiple logistic regression method was used to evaluate the adjusted odds ratios for the utilization of CHPs. For patients with COPD, there was an average of 6.31 CHPs in a single prescription. The most frequently prescribed CHP for COPD was Xiao-Qing-Long-Tang (XQLT) (2.6%), and the most commonly used combination of two formula CHPs was XQLT with Ma-Xing-Gan-Shi-Tang (MXGST) (1.28%). The most commonly used single CHP for COPD was Bulbus Fritillariae (3.65%), and the most commonly used combination of two single CHPs was Bulbus Fritillariae with Puerariae Lobatae (1.09%). These results provide information regarding personalized therapies and may promote further clinical experiments and pharmacologic research on the use of CHPs for the management of COPD. Furthermore, we found that TCM usage was more prevalent among men, younger, manual workers, residents of Northern Taiwan, and patients with chronic bronchitis and asthma. This information on the distribution of TCM usage around the country is valuable to public health policymakers and clinicians.

Entities:  

Keywords:  Chinese Herbal Products; Chronic Obstructive Pulmonary Disease; Couplet Medicinal; Pharmacoepidemiology; Prescription Pattern

Mesh:

Substances:

Year:  2017        PMID: 28231744     DOI: 10.1142/S0192415X17500148

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  14 in total

1.  Long-term survival in a patient with pulmonary spindle cell carcinoma treated with traditional Chinese medicine.

Authors:  Wenyuan Li; Maoyan Chen; Yuanhong Zhao
Journal:  BMJ Case Rep       Date:  2018-09-08

2.  Effect of Bufei Yishen Granules Combined with Electroacupuncture in Rats with Chronic Obstructive Pulmonary Disease via the Regulation of TLR-4/NF-κB Signaling.

Authors:  Jindi Ma; Yange Tian; Jiansheng Li; Lanxi Zhang; Mingming Wu; Lihua Zhu; Shuai Liu
Journal:  Evid Based Complement Alternat Med       Date:  2019-05-29       Impact factor: 2.629

3.  Chinese oral herbal paste for the treatment of stable chronic obstructive pulmonary disease: Protocol for a systematic review and meta-analysis.

Authors:  Yan Zeng; Yu Li; Hua Wei; Chan Xiong; Li Liao; Ti-Wei Miao; Bing Mao; Juan-Juan Fu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

4.  Effect of Panax Ginseng (G115) Capsules versus Placebo on Acute Exacerbations in Patients with Moderate to Very Severe COPD: A Randomized Controlled Trial.

Authors:  Yuanbin Chen; Lin Lin; Lei Wu; Yinji Xu; Johannah L Shergis; Anthony L Zhang; Zehuai Wen; Christopher Worsnop; Cliff Da Costa; Frank Thien; Charlie C Xue
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-03-27

Review 5.  Unraveling the Molecular Mechanism of Traditional Chinese Medicine: Formulas Against Acute Airway Viral Infections as Examples.

Authors:  Yi Shin Eng; Chien Hsing Lee; Wei Chang Lee; Ching Chun Huang; Jung San Chang
Journal:  Molecules       Date:  2019-09-27       Impact factor: 4.411

6.  Chinese Herbal Products for Non-Motor Symptoms of Parkinson's Disease in Taiwan: A Population-Based Study.

Authors:  Chien-Hung Lin; Hsienhsueh Elley Chiu; Szu-Ying Wu; Shih-Ting Tseng; Tzu-Chan Wu; Yu-Chiang Hung; Chung Y Hsu; Hsuan-Ju Chen; Sheng-Feng Hsu; Chun-En Kuo; Wen-Long Hu
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

7.  Mechanism of Action of Bu-Fei-Yi-Shen Formula in Treating Chronic Obstructive Pulmonary Disease Based on Network Pharmacology Analysis and Molecular Docking Validation.

Authors:  Longchuan Wu; Yu Chen; Jiao Yi; Yi Zhuang; Lei Cui; Chunhui Ye
Journal:  Biomed Res Int       Date:  2020-11-26       Impact factor: 3.411

8.  A retrospective study of Yiqibushenhuoxue decoction for the treatment of chronic obstructive pulmonary disease.

Authors:  Zhuying Li; Chunyan Tian; Xuehui Wang; Liqin Wang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

9.  Ma Xing Shi Gan Decoction Attenuates PM2.5 Induced Lung Injury via Inhibiting HMGB1/TLR4/NFκB Signal Pathway in Rat.

Authors:  Yu-Xiang Fei; Bo Zhao; Qi-Yang Yin; Yan-Ying Qiu; Guang-Hui Ren; Bo-Wen Wang; Ye-Fang Wang; Wei-Rong Fang; Yun-Man Li
Journal:  Front Pharmacol       Date:  2019-11-14       Impact factor: 5.810

10.  Association of Chinese Herbal Medicines Use with Development of Chronic Obstructive Pulmonary Disease Among Patients with Rheumatoid Arthritis: A Population-Based Cohort Study.

Authors:  Miao-Chiu Lin; Hanoch Livneh; Wei-Jen Chen; Ming-Chi Lu; Ning-Sheng Lai; Tzung-Yi Tsai
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.